G
CLOV icon

Gainplan’s Clover Health Investments CLOV Stock Holding History

Gainplan’s Portfolio CLOV Stock Details CLOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,205
Closed -$8.1K – 68
2024
Q1 		$8.1K Sell
10,205
-2,194
-18% -$2K ﹤0.01% 70
2023
Q4 		$11.8K Sell
12,399
-5,153
-29% -$5.06K 0.01% 50
2023
Q3 		$19K Buy
+17,552
New +$20.9K 0.03% 42
2023
Q2 		– Sell
-10,892
Closed -$9.21K – 47
2023
Q1 		$9.21K Buy
10,892
+882
+9% +$966 0.01% 41
2022
Q4 		$9.3K Buy
+10,010
New +$13.4K 0.02% 36
2022
Q3 		– Sell
-31,841
Closed -$58K – 28
2022
Q2 		$58K Sell
31,841
-13,926
-30% -$37K 0.04% 37
2022
Q1 		$162K Buy
45,767
+13,457
+42% +$39K 0.12% 48
2021
Q4 		$120K Sell
32,310
-3,038
-9% -$18.6K 0.05% 60
2021
Q3 		$245K Buy
35,348
+14,689
+71% +$126K 0.11% 49
2021
Q2 		$267K Buy
+20,659
New +$203K 0.11% 65

Other funds holding CLOV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gainplan's CLOV Position: Q2 2024 in Review

Gainplan sold out of Clover Health Investments (CLOV) in Q2 2024, closing a stake of 10,205 shares — an estimated $8.1K sold.

Gainplan first reported a position in CLOV in Q2 2021 and held it in 10 quarters. The position peaked at $267K in Q2 2021. 127 funds tracked by Wall St. Rank hold CLOV as of Q2 2024.

  • Gainplan reported no remaining Clover Health Investments position as of Q2 2024 after selling out during the quarter.
  • Gainplan sold 10,205 Clover Health Investments shares in Q2 2024, an estimated $8.1K.
  • Gainplan first reported a position in Clover Health Investments in Q2 2021 and held it in 10 quarters.
  • Gainplan's Clover Health Investments position peaked at $267K in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Clover Health Investments as of Q2 2024.

Based on Gainplan's 13F filing for Q2 2024, filed 12 Jul 2024.